Age

15–65

Sex

ALL

Healthy volunteers

Not accepted

1. Age ≥15 years and ≤65 years.
2. Newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) according to WHO diagnostic criteria, with CD19 expression ≥ 20%
3. De novo patients with no prior induction therapy (excluding hydroxyurea and corticosteroid use for ≤ 5 days)
4. ECOG performance status score 0-3.
5. Liver function: Total bilirubin ≤ 3 times the upper limit of normal (ULN); alanine transaminase (ALT) ≤ 3×ULN; aspartate transaminase (AST) ≤ 3×ULN; (leukemic infiltration is excluded).
6. Renal function: Creatinine clearance rate (CrCl) ≥ 30 mL/min
7. Able to understand and voluntarily participate in the study, and provide written informed consent

1. Philadelphia chromosome-positive (Ph+, BCR-ABL1+) ALL
2. T-cell acute lymphoblastic leukemia
3. Mature B-cell leukemia/lymphoma, B-cell lymphoblastic lymphoma, extramedullary invasion
4. Acute mixed phenotype acute leukemia (MPAL)
5. Central nervous system (CNS) leukemia
6. HIV infection
7. Positive HBV-DNA or HCV-RNA
8. New York Heart Association (NYHA) functional class ≥ II, or other conditions deemed unsuitable for enrollment by the investigator
9. Pregnant or lactating patients
10. Patients who refuse to enroll in the study

Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia